Eloxx Plans to Advance ZKN-013 as Oral Treatment for RDEB and JEB

Eloxx Plans to Advance ZKN-013 as Oral Treatment for RDEB and JEB

303594

Eloxx Plans to Advance ZKN-013 as Oral Treatment for RDEB and JEB

Eloxx Pharmaceuticals announced ZKN-013 as its lead oral treatment candidate for recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB) caused by nonsense mutations in the COL7A1 gene. Preclinical safety and toxicology studies, required to secure U.S. Food and Drug Administration (FDA) approval for clinical trials of ZKN-013, are expected to begin by year’s end. Eloxx anticipates to file such a request to the FDA in 2022. ZKN-013 was originally developed by Zikani Therapeutics, which was acquired…

You must be logged in to read/download the full post.